logo

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Please see package insert for additional information and possible updates. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.    [  Read the disclaimer    |   <<Back      |  Other Immunoglobulins led  ]
CLINICAL PHARMACOLOGY INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION HOW SUPPLIED

CLINICAL PHARMACOLOGY: top of page

Initial U.S. Approval:  2014

Mechanism of Action: Recombinant Human Hyaluronidase of HYQVIA increases dispersion and absorption of the Immune Globulin Infusion 10% (Human). The Immune Globulin Infusion 10% (Human) of HYQVIA supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents. The Immune Globulin Infusion 10% (Human) also contains a spectrum of antibodies capable of interacting with and altering the activity of cells of the immune system as well as antibodies capable of reacting with cells such as erythrocytes. The role of these antibodies and the mechanisms of action of IgG in the Immune Globulin Infusion 10% (Human) of HYQVIA have not been fully elucidated.
Hyaluronan is a polysaccharide found in the extracellular matrix of the connective tissue8. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a very fast turnover with a half-life of approximately 0.5 days. The Recombinant Human Hyaluronidase of HYQVIA increases permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan.In the doses administered, Recombinant Human Hyaluronidase of HYQVIA acts locally. The effects of the hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours.

INDICATIONS AND USAGE  top of page


INDICATIONS AND USAGE:
HYQVIA is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of Primary Immunodeficiency (PI) in adults.
Limitation of Use:
Safety and efficacy of chronic use of recombinant human hyaluronidase in HYQVIA have not been established in conditions other than PI.

DOSAGE AND ADMINISTRATION  top of page

Drug UPDATES:  HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]
Solution for subcutaneous administration
[Drug information  /  PDF]  
Dosing:  Click (+) next to Dosage and Administration section (drug info link)

HOW SUPPLIED top of page

HOW SUPPLIED:  [Several strengths available]: HYQVIA is a dual vial unit consisting of one vial of a liquid solution containing Immune Globulin Infusion 10% (Human) and one vial of a liquid solution containing 160 U/mL Recombinant Human Hyaluronidase.
Immune Globulin Infusion 10% (Human) / Recombinant Human Hyaluronidase
Grams Protein /  Units
2.5                  / 200
5.0                 / 400
10.0               / 800

REFERENCE


[Drug information  /  PDF]  
Dosing:  Click (+) next to Dosage and Administration section (drug info link)
Medical Calculators - A thru Z
Lab Values - A thru Z